Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Mild to Moderate Persistent Asthma
Interventions: Activation Energy Serum; Dietary Supplement
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Angina
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 21
States / cities: Carmichael, California • Fresno, California • Irvine, California + 18 more

Conditions: Cystic Fibrosis
Interventions: BIIL 283 BS (Amelubent); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more

Conditions: Postoperative Pain, Inflammation, Osteoarthritis
Interventions: Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo; Drug
Lead sponsor: Thomas L Bradbury; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Cerebral Palsy
Interventions: Standardized Constraint-Induced Movement Therapy, Vibration, Placebo (for vibration); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 3 Years to 9 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Healthy Volunteers
Interventions: PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Heat Strain, Healthy Volunteer Study, Kidney Dysfunction
Interventions: Vitamin B3; Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Preterm Premature Rupture of Membranes
Interventions: indomethacin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post Herpetic Neuralgia
Interventions: Pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 82
States / cities: Gulf Shores, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more

Conditions: Opioid-use Disorder, Pain, Postoperative
Interventions: NSS-2 Bridge, Inactive NSS-2 Bridge, Active control; Device · Other
Lead sponsor: Grace Lim, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Episodic Migraine Headache
Interventions: LBR-101 High Dose, LBR-101 Low Dose, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 63
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more

Conditions: Ascites, Liver Cirrhosis
Interventions: satavaptan (SR121463B); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Intercritical Gout
Interventions: Placebo, Rilonacept 80 mg, Rilonacept 160 mg; Other · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more

Conditions: Schizophrenia
Interventions: AZD8529, Placebo to match AZD8529; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Cocaine Dependence
Interventions: N-acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions: Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more

Conditions: Osteoarthritis
Interventions: Modafinil, Gabapentin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Crohn's Disease
Interventions: Mirikizumab, Ustekinumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 1,158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 140
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more

Conditions: Alzheimer Disease, Diabetes Mellitus, Type 2
Interventions: Tailored Lighting Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Albany, New York • New York, New York

Conditions: Brain Concussion
Interventions: MedX Health Console model 1100, MedX Health Console model 1100-placebo; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 11 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Waltham, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: JTT-662, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Steroids in Total Knee Arthroplasty

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Sensory Stimulation During CIMT

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response

Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Pain Expectations in Subjects With Osteoarthritis

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Light and the Effect on Metabolic Syndrome and Alzheimer's Disease

LED Therapy for the Treatment of Concussive Brain Injury

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes